AMAG Pharmaceuticals Inc. has gotten fast-track designation from federal regulators for its new MRI diagnostic imaging agent. The Cambridge, Mass.-based company (Nasdaq: AMAG) said the U.S. Food and Drug Administration granted the special status for ferumoxytol, which will help improve the assessment of peripheral artery disease in patients with known or suspected chronic kidney disease.
